TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00727571

Intervention type: OTHER
Intervention: Observations
Description: This is a non-interventional, observational study; no investigational product is being used

Intervention type: OTHER
Intervention: Observations
Description: This is a non-interventional, observational study; no investigational product is being used

Intervention type: OTHER
Intervention: Observations
Description: This is a non-interventional, observational study; no investigational product is being used

Intervention type: OTHER
Intervention: Observations
Description: This is a non-interventional, observational study; no investigational product is being used
Study: NCT03682900

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Click City®: Tobacco
Description: A computer-based program assigned to students designed to prevent subsequent tobacco use. Students complete one 15 to 20 minute lesson two times a week for four weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Tobacco Curriculum
Description: Students complete their usual curriculum designed to prevent tobacco use.
Study: NCT01684553

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Slow eating condition
Description: The subjects were asked to eat their meal slowly during the slow eating condition

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fast eating condition
Description: The subjects were asked to eat their meal quickly during the fast eating condition
Study: NCT00583895

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Five patients will receive placebo cream on both limbs twice daily for 14 days with an additional morning application on Day 15.
Study: NCT04724993

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online Aerobic Dance Exercises
Description: Online aerobic dance exercises will be performed with observance of physiotherapist. They will record their daily physical activity.
Study: NCT01261078

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intrathecal 8 mg of bupivacaine only

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epinephrine 25
Description: intrathecal 8 mg of bupivacaine mixed with 25 mcg of epinephrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine 50
Description: intrathecal 8 mg of bupivacaine mixed with 50 mcg of epinephrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epinephrine 100
Description: intrathecal 8 mg of bupivacaine mixed with 0.1 mg of epinephrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epi 200
Description: intrathecal bupivacaine 8 mg with 200 mcg of epinephrine
Study: NCT01199861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: Fingolimod 0.5 mg capsules for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules for oral administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal influenza vaccine
Description: Commercially available injectable influenza vaccine for the 2010/11 influenza season.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Seasonal influenza vaccine
Description: Commercially available injectable influenza vaccine for the 2010/11 influenza season.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus toxoid vaccine
Description: Commercially available tetanus toxoid vaccine booster injection.
Study: NCT04724993

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity Counseling
Description: Physical activity and exercise will ve explained to the participants.And they will record their daily physical activity.
Study: NCT03638765

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DCVax-Direct
Description: activated, autologous dendritic cells
Study: NCT01199861

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Tetanus toxoid vaccine
Description: Commercially available tetanus toxoid vaccine booster injection.
Study: NCT00954915

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: teplizumab
Description: Cohorts 1-5: escalating doses of subcutaneously administered teplizumab; cohort 6: intravenous administration of maximum tolerated subcutaneous dose.
Study: NCT02227862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mylan's insulin glargine
Description: All patients will be shifted from their current mealtime insulin to insulin lispro at the start of the run-in period, and will continue on this for the complete trial. During the 6 week run-in period the doses of Lantus® and insulin lispro will be titrated (if required) to ensure diabetes control. After the run-in period, patients will be randomized to receive either Mylan's insulin glargine (in place of Lantus®), or to continue on Lantus®. During the period from 12 to 24 weeks dose titration will be kept to a minimum.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lantus®
Description: All patients will be shifted from their current mealtime insulin to insulin lispro at the start of the run-in period; and will continue on this for the complete trial. During the 6week run-in period the doses of Lantus® and insulin lispro will be titrated (if required) to ensure diabetes control. After the run-in period, patients will be randomized to receive either Mylan's insulin glargine (in place of Lantus®), or to continue on Lantus®. During the period from 12 to 24 weeks dose titration will be kept to a minimum.
Study: NCT02865408

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Peptamen 1.5% via enteral
Description: Study patients in this group will be prescribed 1.0 g/kg/d of protein using standard enteral Peptamen 1.5%. Based on current compliance or tolerance statistics, investigators expect patients to only receive 50-60% of these prescribed doses; effective protein intake will therefore be approximately 0.5-0.6 g/kg/d.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Peptamen 1.5% via enteral
Description: Study patients in this group will be prescribed 1.0 g/kg/d of protein using standard enteral Peptamen 1.5%. Based on current compliance or tolerance statistics, investigators expect patients to only receive 50-60% of these prescribed doses; effective protein intake will therefore be approximately 0.5-0.6 g/kg/d.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Peptamen 1.5% via enteral
Description: Study patients in this group will be prescribed 1.0 g/kg/d of protein using standard enteral Peptamen 1.5%. Based on current compliance or tolerance statistics, investigators expect patients to only receive 50-60% of these prescribed doses; effective protein intake will therefore be approximately 0.5-0.6 g/kg/d.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prosol 20% IV to 1.75g/kg/day
Description: Patients in group 2 will receive Peptamen 1.5% but in addition, will receive sufficient intravenous amino acid supplements (Prosol 20%) to achieve an effective fixed dose of 1.75 g/kg/day.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prosol 20% IV to 2.5g/kg/day
Description: Patients in this group will receive intravenous amino acids, Prosol 20% in addition to standard enteral Peptamen 1.5% to achieve an effective protein intake of 2.5 g/kg/d.
Study: NCT04545762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given intravenously (IV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD19 CAR-T cells
Description: Single infusion
Study: NCT00005842

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Study: NCT01919190

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EXPAREL
Description: TAP with EXPAREL

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01977469

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low intensity resistance training
Description: The LIRT group initiated the resistance training for UL with 30% of the 1RM, with 5% increases each nine sessions; therefore, the maximum load was 45% of the 1RM. The LL training initiated with 30% of the 1RM, increasing 7% each nine sessions, thus, the maximum load was 51% of the 1RM. Each exercise session consisted of three sets of 15 repetitions, with a 2 minutes interval between sets.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity resistance training
Description: the initial load for HIRT group was 60% of 1RM for UL with 5% increases each nine sessions; therefore, the maximum load reached 75% of the 1RM. The LL training initiated with 60% of the 1RM with 7% increments each nine sessions, as a result, the maximum load after 36 sessions was 81% of the 1RM. These patients underwent three sets of eight repetitions, with two minutes intervals between sets.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: Patients underwent an aerobic training in cycle ergometer, with load intensity determined as the same load the patient presented a VO2 value of 70-80% of the peak VO2 obtained in the symptom-limited CPET. Each session of aerobic training lasted 20-30min according to patient's tolerance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: Patients underwent an aerobic training in cycle ergometer, with load intensity determined as the same load the patient presented a VO2 value of 70-80% of the peak VO2 obtained in the symptom-limited CPET. Each session of aerobic training lasted 20-30min according to patient's tolerance.
Study: NCT03489759

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ViE15-A
Description: The type of dialytic treatment that will be used during the study will be continuous venous hemofiltration (CVVH-Continuous veno-venous hemofiltration). The filter will be ViE15-A.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: REXEED-15A
Description: The type of dialytic treatment that will be used during the study will be continuous venous hemofiltration (CVVH-Continuous veno-venous hemofiltration). The filter will be REXEED-15A.
Study: NCT02297451

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Proximal radial/ulnar artery as inflow
Description: Proximal radial/ulnar artery used as inflow
Study: NCT00643877

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preoperative hepatic and regional arterial chemotherapy using oxaliplatin, MMC and FUDR
Description: PHRAC which included of two parts(common hepatic artery chemotherapy and main tumor supplying artery chemotherapy) was performed 7 days before surgery： common hepatic artery chemotherapy: FUDR 500mg, Oxaliplatin 50mg and MMC 10mg main tumor supplying artery chemotherapy: FUDR 500mg, Oxaliplatin 50mg and MMC 10mg

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: surgery
Description: radical surgery only
Study: NCT02840409

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinblastine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study: NCT00929539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTT-130
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTT-130
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTT-130
Description: Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: JTT-130 Placebo
Description: Tablets
Study: NCT01106326

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Teens participating in this study will have:~1. directly observed administration of their daily preventive asthma medication at school, by the school nurse, for the first 6-8 weeks of the study~2. three counseling sessions with a study nurse trained in principles of motivational interviewing (MI), that are designed to enhance the teen's motivation to change health behaviors, with a focus on adherence to evidence-based preventive care guidelines (e.g.; preventive medications).
Study: NCT01512407

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolisation using cisplatin-lipiodol mixture
Description: Cisplatin-lipiodol mixture was infused through catheter placed at hepatic artery followed by gelfoam embolisation. This is performed 4 to 6 weeks after surgery
Study: NCT02607319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemiparin sodium
Description: Bemiparin sodium 3,500 IU will be started on the evening of the same day of embryo transfer and until the day of pregnancy test. If the test is positive, Bemiparin will be discontinued by the end of the 12th week of gestation.
Study: NCT04217408

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: Active continuous deep brain stimulation of the ventral capsule/ventral striatum

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: Active continuous deep brain stimulation of the ventral capsule/ventral striatum
Study: NCT01144936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-985 or matching placebo
Description: low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-985 or matching placebo
Description: high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-985 or matching placebo
Description: dose TBD
Study: NCT01341366

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fast-track perioperative program
Description: Preoperative counseling, no preoperative fasting, short-acting anesthetics, continuous infiltration of wound with local anesthetic agent, non-opioid pain management, the use of chewing gum, and early postoperative feeding and mobilization

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional perioperative program
Description: Preoperative fasting, standard anesthetic management with no intraoperative fluid restriction, opioid pain management, no chewing gum, feeding/mobilization according to attending surgeon
Study: NCT00951288

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Saffron
Description: Saffron 20 mg/day supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00755196

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AN2728
Description: AN2728 Ointment, 5%, twice daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ointment vehicle
Description: Ointment vehicle, twice daily for 12 weeks
Study: NCT03840057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Injection
Description: Azithromycin, a semi-synthetic macrolide antibiotic derived from erythromycin. The role of azithromycin as a prokinetic agent was first reported in a retrospective cohort study, which showed azithromycin to be equivalent to erythromycin in accelerating gastric emptying in patients with gastroparesis. The aim of this intervention arm is to evaluate the effectiveness of azithromycin as a prokinetic agent in the management of UGIB.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide Injectable Solution
Description: Metoclopramide, a 5-HT4 agonist and a dopamine D2-receptor antagonist, is approved for short-term treatment of gastroparesis. The use of metoclopramide as a prokinetic agent in the setting of UGIB has been previously studied, but the number of subject involved was too low to adequately power the studies. The aim of this intervention arm is to further evaluate the effectiveness of metoclopramide as a prokinetic agent in the management of UGIB.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride 0.9%
Description: Normal saline is used as a placebo control.
Study: NCT01406795

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gore Viabahn Heparin Coated Stent
Description: For subjects deemed to be suffering from chronic venous insufficiency of the femoral or popliteal veins, a Gore Viabahn stent will be implanted during a venoplasty procedure to determine whether the vein will stay open.
Study: NCT04506242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: PD-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: VEGFR2
Study: NCT05618470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wumeiwan Jiawei Fang
Description: orally administered Wumeiwan Jiawei Fang prescription granules, 1 dose a day, twice a day, once for 14 days, for 42 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: botulinum toxin A
Description: Botulinum toxin (Lanzhou Biopharmaceutical Co., LTD.) was injected into the medial side of the upper eyelid, the lateral side of the upper eyelid, the lateral side of the lower eyelid, and the temporal orbicularis oculi muscle of the lateral canthus. The botulinum toxin type A was diluted into 50IU/ML with normal saline and injected with a 1ml skin test syringe (4\\ 5-gauge needle), and 2.5IU was injected into each point. A total of 1 injection.
Study: NCT03830164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Given PO

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin E Compound
Description: Given PO
Study: NCT01208012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Victoza®
Description: Patients taking Metformin at individual dose and Liraglutide 0.6 mg once daily for the 1st week, 1.2 mg daily for another 5 weeks, 1.8 mg daily for another 6 weeks. When arrived at the dosage of 1.8 mg daily and the dose is not tolerated by the patient, the dose of Liraglutide can be decreased.Liraglutide is injected in the subcutaneous tissue once daily
Study: NCT05360316

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ESWT
Description: extracorporeal shock wave therapy
Study: NCT00503152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benazepril
Description: After one month wash-out from previous RAS (ARB or ACE) inhibitor therapy, patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day). If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: After one month wash-out from previous RAS (ARB or ACE) inhibitor therapy, patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day). If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benazepril/Valsartan
Description: After one month wash-out from previous RAS (ARB or ACE) inhibitor therapy, patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day). If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
Study: NCT02835482

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femtolaser surgery

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Femtolaser surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phacoemulsification

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Phacoemulsification
Study: NCT03920657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: Fixed dose of 3.5 mg/kg/day of DFX FCT
Study: NCT00305045

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Magnetic pulses to specified brain structures.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Magnetic pulses to specified brain structures.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Magnetic pulses to specified brain structures.
Study: NCT04339465

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CARE-FAM
Description: CARE-FAM is a family-based intervention for the diagnostic, early detection and early treatment of mental health issues of children affected by rare diseases, their siblings and their parents. CARE-FAM is a brief low-frequency intervention comprising six to eight sessions per family over a period of six months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CARE-FAM
Description: CARE-FAM is a family-based intervention for the diagnostic, early detection and early treatment of mental health issues of children affected by rare diseases, their siblings and their parents. CARE-FAM is a brief low-frequency intervention comprising six to eight sessions per family over a period of six months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WEP-CARE
Description: WEP-CARE is an online-intervention that addresses parents of children and adolescents affected by rare diseases. The program is based on principles of cognitive-behavioral writing therapy. Supported by trained professionals, the participants perform 12 standardized writing tasks on a secured internet platform

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WEP-CARE
Description: WEP-CARE is an online-intervention that addresses parents of children and adolescents affected by rare diseases. The program is based on principles of cognitive-behavioral writing therapy. Supported by trained professionals, the participants perform 12 standardized writing tasks on a secured internet platform